Skip to Main Content
Table 2.

gli2 MO injections into yot–/+× yot–/+crosses*

gli2 MO injectedyot-/- phenotype([UNK]nk2.2, nomyoD)yot-/+ phenotype (wt nk2.2,[UNK]myoD)Wild-type (nk2.2, myoD)Total
Uninjected siblings* 62 (23%) 141 (51%) 73 (26%) 276 
1 ng 3 (5%) 15 (24%) 45 (71%) 63 
3-7 ng 18 (23%) 61 (77%) 79 
10-15 ng 25 (14%) 148 (86%) 173 

 
nk2.1b reduced in di.
 
Partial nk2.1b rescue
 
wt nk2.1b
 

 
Uninjected 26 (30%) 60 (70%) 86 
6 ng 8 (21%) 30 (79%) 38** 
10 ng 1 (2%) 39 (98%) 40** 
gli2 MO injectedyot-/- phenotype([UNK]nk2.2, nomyoD)yot-/+ phenotype (wt nk2.2,[UNK]myoD)Wild-type (nk2.2, myoD)Total
Uninjected siblings* 62 (23%) 141 (51%) 73 (26%) 276 
1 ng 3 (5%) 15 (24%) 45 (71%) 63 
3-7 ng 18 (23%) 61 (77%) 79 
10-15 ng 25 (14%) 148 (86%) 173 

 
nk2.1b reduced in di.
 
Partial nk2.1b rescue
 
wt nk2.1b
 

 
Uninjected 26 (30%) 60 (70%) 86 
6 ng 8 (21%) 30 (79%) 38** 
10 ng 1 (2%) 39 (98%) 40** 
[UNK]

: reduced; di: diencephalon.

*

Expected genotypes: 25% yot-/-, 50%yot-/+, 25% homozygous wild type.

**

All gli2 MO-injected embryos showed expanded nk2.1b in the telencephalon.

Close Modal

or Create an Account

Close Modal
Close Modal